We are live on ! Find out more
AKYA

Akoya BioSciences
AKYA

Delisted

AKYA was delisted on the 7th of July, 2025.

Back to rankings

0 hedge funds and large institutions have $0 invested in Akoya BioSciences in 2025 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 58 closing their positions.

New
Increased
Maintained
Reduced
Closed

25.1% less ownership

Funds ownership: 25.1% → 0% (-25%)

100% less funds holding

Funds holding: 58 → 0 (-58)

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

100% less capital invested

Capital invested by funds: $16.3M → $0 (-$16.3M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 58

Holders
–
Holders Change
-58
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
58
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
BWLSA
Blue Water Life Science Advisors
California
-$6.11M
2
OBAM
ODDO BHF Asset Management
France
-$2.46M
3
Vanguard Group
Vanguard Group
Pennsylvania
-$1.55M
4
PAPAIJV
Paragon Associates & Paragon Associates II Joint Venture
Texas
-$872K
5
TC
Trium Capital
United Kingdom
-$787K
Name Holding Trade Value Shares
Change 		Change in
Stake
HF
26
HRT Financial
New York
– -$62K -47,706 Closed
AQR Capital Management
27
AQR Capital Management
Connecticut
– -$47.3K -36,409 Closed
RC
28
Rangeley Capital
Connecticut
– -$42.9K -33,035 Closed
VPIM
29
Vanguard Personalized Indexing Management
California
– -$38.3K -29,440 Closed
TCA
30
Transcend Capital Advisors
New Jersey
– -$35.9K -27,602 Closed
YIH
31
Y-Intercept (HK)
Hong Kong
– -$34.4K -26,464 Closed
JG
32
Jain Global
New York
– -$29.8K -22,960 Closed
HighTower Advisors
33
HighTower Advisors
Illinois
– -$26K -20,000 Closed
PAS
34
Point72 Asia (Singapore)
Singapore
– -$25.3K -19,456 Closed
XT
35
XTX Topco
Cayman Islands
– -$21.3K -16,402 Closed
TRCT
36
Tower Research Capital (TRC)
New York
– -$20.8K -16,025 Closed
RhumbLine Advisers
37
RhumbLine Advisers
Massachusetts
– -$13.9K -10,700 Closed
CFO
38
Callan Family Office
Pennsylvania
– -$13.6K -10,465 Closed
Fidelity Investments
39
Fidelity Investments
Massachusetts
– -$4.49K -3,450 Closed
Carson Wealth (CWM LLC)
40
Carson Wealth (CWM LLC)
Nebraska
– -$3K -2,393 Closed
Group One Trading
41
Group One Trading
Illinois
– -$2.61K -2,010 Closed
SIA
42
Sit Investment Associates
Minnesota
– -$2K -1,854 Closed
Bank of America
43
Bank of America
North Carolina
– -$2.3K -1,771 Closed
CSS
44
Cubist Systematic Strategies
Connecticut
– -$2.14K -1,646 Closed
Royal Bank of Canada
45
Royal Bank of Canada
Ontario, Canada
– -$2K -1,486 Closed
Barclays
46
Barclays
United Kingdom
– -$1.84K -1,412 Closed
BNP Paribas Financial Markets
47
BNP Paribas Financial Markets
France
– -$1.67K -1,287 Closed
Raymond James Financial
48
Raymond James Financial
Florida
– -$1.33K -1,026 Closed
Citigroup
49
Citigroup
New York
– -$1.21K -931 Closed
Nisa Investment Advisors
50
Nisa Investment Advisors
Missouri
– -$772 -594 Closed
1
2
3

AKYA Hedge Fund Activity: Q3 2025 in Review

0 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in Akoya BioSciences (AKYA) for Q3 2025, worth a combined $0 — down 100% from $16.3M a quarter earlier.

Sellers outnumbered buyers: 58 funds closed out of AKYA and 0 opened new positions — a net loss of 58 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Blue Water Life Science Advisors, exiting entirely with an estimated $6.11M sold.

  • 0 institutional investors held Akoya BioSciences (AKYA) as of Q3 2025, down from 58 in Q2 2025.
  • Funds reported $0 of Akoya BioSciences stock for Q3 2025, down 100% quarter-over-quarter.
  • 0 funds opened new Akoya BioSciences positions in Q3 2025 and 58 closed out, a net change of -58 holders.
  • The largest Akoya BioSciences seller in Q3 2025 was Blue Water Life Science Advisors, an estimated $6.11M sold.

Based on aggregated 13F filings for Q3 2025.